Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

<p>Phosphoproteins</p>

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Xiaoqing Cheng (16918496) (author)
Weitere Verfasser: Yirui Sun (16918499) (author), Maureen Highkin (16918502) (author), Nagalaxmi Vemalapally (16918505) (author), Xiaohua Jin (16918508) (author), Brandon Zhou (16918511) (author), Julie L. Prior (16918514) (author), Ashley R. Tipton (16918517) (author), Shunqiang Li (15123195) (author), Anton Iliuk (16918520) (author), Samuel Achilefu (11605234) (author), Ian S. Hagemann (15026769) (author), John R. Edwards (16918523) (author), Ron Bose (15045749) (author)
Veröffentlicht: 2025
Schlagworte:
Cancer
Molecular and Cellular Biology
Therapeutic Research and Development
Methods and Technology
Biological Agents & Therapies
Antibody-drug conjugates
Antireceptors
Breast Cancer
Cell Cycle
CDKs and CDK inhibitors
Preclinical Models
Organoids
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:<p>Phosphoproteins</p>

Ähnliche Einträge